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Abstract
Background: Data on absolute risks of outcomes and patterns of drug use in cost-effectiveness analyses are often based on
randomised clinical trials (RCTs). The objective of this study was to evaluate the external validity of published cost-
effectiveness studies by comparing the data used in these studies (typically based on RCTs) to observational data from
actual clinical practice. Selective Cox-2 inhibitors (coxibs) were used as an example.
Methods and Findings: The UK General Practice Research Database (GPRD) was used to estimate the exposure
characteristics and individual probabilities of upper gastrointestinal (GI) events during current exposure to nonsteroidal
anti-inflammatory drugs (NSAIDs) or coxibs. A basic cost-effectiveness model was developed evaluating two alternative
strategies: prescription of a conventional NSAID or coxib. Outcomes included upper GI events as recorded in GPRD and
hospitalisation for upper GI events recorded in the national registry of hospitalisations (Hospital Episode Statistics) linked to
GPRD. Prescription costs were based on the prescribed number of tables as recorded in GPRD and the 2006 cost data from
the British National Formulary. The study population included over 1 million patients prescribed conventional NSAIDs or
coxibs. Only a minority of patients used the drugs long-term and daily (34.5% of conventional NSAIDs and 44.2% of coxibs),
whereas coxib RCTs required daily use for at least 6–9 months. The mean cost of preventing one upper GI event as recorded
in GPRD was US$104k (ranging from US$64k with long-term daily use to US$182k with intermittent use) and US$298k for
hospitalizations. The mean costs (for GPRD events) over calendar time were US$58k during 1990–1993 and US$174k during
2002–2005. Using RCT data rather than GPRD data for event probabilities, the mean cost was US$16k with the VIGOR RCT
and US$20k with the CLASS RCT.
Conclusions: The published cost-effectiveness analyses of coxibs lacked external validity, did not represent patients in
actual clinical practice, and should not have been used to inform prescribing policies. External validity should be an explicit
requirement for cost-effectiveness analyses.
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Many countries require health technology assessments when
deciding on adopting new healthcare technologies. Recently, the
American College of Physicians recommended the establishment
of an organization for the generation and review of cost-
effectiveness analyses [1]. In England and Wales, formal cost-
effectiveness analyses are now required and several years ago the
National Institute for Health and Clinical Excellence (NICE) was
established to balance the financial costs and clinical benefits of
health technologies and evaluate their cost effectiveness [2,3]. It
would be of interest to evaluate the experience in England and
Wales and evaluate whether previous cost-effectiveness analyses
adequately informed and guided medical practice.
Selective cyclooxygenase-2 inhibitors (coxibs) ranked, before
September 2004, among the most commonly used medications in
the world. They were developed to minimize the upper
gastrointestinal (GI) side-effects of conventional nonsteroidal
anti-inflammatory drugs (NSAIDs). There have been at least 33
published studies that evaluated the cost effectiveness of coxibs
(celecoxib, rofecoxib, etoricoxib, or lumiracoxib) relative to that of
conventional NSAIDs [4–36]. Although the use of coxibs has now
changed following the findings of cardiovascular harm [37], they
provide a good example of a drug with recently published cost-
effectiveness analyses that were used to inform prescribing policies
[8,36]. Randomised clinical trial (RCT) data were used for the
estimates of the rates of the upper GI events in all cost-effectiveness
studies, except those conducted prior to the completion of large
RCTs [4–7]. RCT data are still widely used not only for efficacy
estimates but also for costs and incidence estimates [38–40]. While
RCTs undoubtedly provide the best evidence for efficacy, they
may not be the best source of costing data [41]. In addition, it is
unclear whether RCT estimates on the incidence of outcomes
represent the experience of patients in actual clinical practice [42].
However, there has been little empirical investigation of these
issues. The objective of this study was to evaluate the external
validity of published cost-effectiveness studies by comparing the
data used in these studies to observational data from actual clinical
practice and whether these studies should have been used to
inform prescribing policies. Coxibs were used as an example.
Methods
Design of the Cost-Effectiveness Model
A basic cost-effectiveness model was developed evaluating two
alternative strategies: prescription of a conventional NSAID or
coxib. The model estimated the incremental cost of preventing one
upper GI event with coxibs in a large representative UK
population that had been prescribed anti-inflammatory medica-
tion during 1990–2006 for any medical condition. The prescrip-
tions costs and the number of cases with upper GI events during
current exposure to coxibs were compared in a simulation model
to those with conventional NSAIDs.
Risks of Upper GI Events
The upper GI events included clinically symptomatic gastro-
duodenal ulcers and complications such as upper GI hemorrhage.
Two data sources were used to estimate the risks of upper GI
events. Firstly, data were derived from existing RCTs. All
published cost-effectiveness analyses conducted since 2000 used
RCT data for the estimates of the risks of upper GI events [8–36].
Literature was searched for large RCTs (including over 2,000
patients) or meta-analyses of RCTs with prevention of upper GI
events as primary outcome. A total of 11 large RCTs or meta-
analyses was identified [43–53]. Secondly, data from actual clinical
practice were used to estimate the absolute risk of upper GI events
among patients using NSAIDs and coxibs. All patients aged 40 y
or older prescribed conventional NSAIDs or coxibs and registered
in the General Practice Research Database (GPRD) were
identified. The GPRD comprises the anonymized computerized
medical records of general practitioners (GPs). GPs play a key role
in the UK health care system, as they are responsible for primary
health care and specialist referrals. Patients are affiliated to a
practice, which centralizes the medical information from the GPs,
specialist referrals, and hospitalizations. The data recorded in the
GPRD include demographic information, prescription details,
clinical events, preventive care provided, specialist referrals, and
hospital admissions and their major outcomes [54]. GPRD data
collection started in 1987 and currently includes data on over 10
million patients. Two outcomes were measured and considered
separately in the analyses. The first outcome concerned a GPRD
record of upper GI events (as based on a GP diagnosis or based on
a hospital or consultant letter as recorded into GPRD by the GP).
The second outcome concerned hospitalizations for upper GI
events, as obtained from the national registry of hospital
admissions in England (Hospital Episode Statistics). Each hospital
records the dates of admission and discharge and diagnoses of
all hospitalizations (data from 2001 to 2006 were used). These
hospital data can now be linked individually and anonymously
to patients in English GPRD practices. The hospitalizations
for upper GI events included the ICD-10 codes for gastric,
duodenal, peptic, or gastrojejunal ulcer and gastritis or duodenitis
(K25–K29).
The GPRD study population was followed from the first
NSAID prescription to the patient’s death, patient’s transfer out of
the general practice, or the last GPRD data collection available for
this study (first quarter of 2006), whichever date came first. The
follow-up of the study population was divided into periods of
current and past exposure, with patients moving between these
exposures. Current exposure was the time-period starting at the
date of a prescription up to 3 mo after the end of the prescription
duration. On average, prescriptions for conventional NSAIDs and
coxibs provided for a treatment of 28 d. Past exposure was the
remaining time of the follow-up period of a patient (i.e., the time
distant from a prescription). In this population, the incidence rates
of upper GI events (i.e., the number of cases per 1,000 person-
years) were estimated during current and past exposure overall
and by age, gender, exposure characteristics, and GI risk factors.
Poisson regression was used to estimate the relative risk (RR) of
upper GI events during current compared to past exposure. All
these analyses were done separately for conventional NSAIDs and
coxibs. In the analysis of conventional NSAIDs, patients were
censored at the first coxib prescription.
Exposure Characteristics
The published cost-effectiveness studies estimated the cost
effectiveness for daily treatment for continuous periods of time
[4–36]. The large RCTs all evaluated long-term NSAID exposure
(ranging from 3 mo to 3 y) in patients with either rheumatoid
arthritis (RA) or osteoarthritis (OA), requiring chronic or
continuous NSAID therapy for the duration of the trial.
The longitudinal prescription histories in GPRD were used to
determine the exposure characteristics (daily or intermittent and
short- or long-term use). The medication possession ratio (i.e., the
proportion of time covered by medication use) was estimated for
each NSAID prescription that had a prior prescription in the 6 mo
before. The medication possession ratio was the expected duration
of NSAID exposure of the previous prescription divided by the
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issued at least 6 mo after the previous NSAID prescriptions were
classified as exposure with long gaps.
First-time exposure was the first NSAID prescription issued at
least 1 y after start of GPRD data collection. At each NSAID
prescription, the number of NSAID prescribed in the 1 y before
was also calculated approximating the prior exposure duration
(short-term, #4; medium-term, 5–11; and long-term exposure,
$11 prior prescriptions). Prescriptions with missing information
on the expected duration of use were classified into a separate
category.
In the UK, ibuprofen is available over the counter without
prescription. Patients need to pay a charge for GP prescriptions,
except elderly and patients with low incomes. Further details on
the prescribing patterns of conventional NSAIDs and coxibs can
be found elsewhere [55,56].
Risk Factors for Upper GI Events
In the GPRD population, the GI risk factors were estimated at
each prescription, including age of 65 y or older, recent prescribing
in the 6 mo before of oral glucocorticoids, or anticoagulants, and
a history of peptic upper GI bleeding, ischemic heart disease,
hypertension, heart, renal or liver failure, or diabetes mellitus.
These risk factors were included in NSAID prescribing guidelines
from NICE [57]. Additional upper GI risk factors measured in
this study included calendar year, the number of visits to the GP in
the 6 to 12 mo before, smoking history and use of alcohol and
body mass index (where available), medical history of OA or RA,
and concomitant prescribing of aspirin or gastro-protective (ulcer-
healing) drugs (British National Formulary 1.3).
Clinical Effects of Coxibs
In order to derive an estimate of the beneficial effects of coxibs
on the risk of upper GI events, a meta-analysis of 11 RCTs was
used. This meta-analysis reported a relative risk reduction (RRR)
of 51% of clinically symptomatic ulcers with coxibs (RR of 0.49;
95% confidence interval [CI] 0.38–0.62) [58]. We assumed in the
simulation model that the risk of upper GI events, as observed in
GPRD in users of conventional NSAIDs, would have been
reduced by 51% if a coxib had been prescribed. Conversely, we
assumed that the risk during current coxib exposure in GPRD
would have increased by 51%, if a conventional NSAID had been
prescribed. In the main analysis, it was assumed that the risk
reduction due to coxibs would start immediately, similar to the
assumptions in the published cost-effectiveness studies [4–36]. As
several RCTs reported an onset of coxib effect only 1 to 6 mo after
starting exposure [45,46,52,53] (i.e., diverging of the risks between
the coxib and control groups), a sensitivity analysis was conducted
assuming a delayed onset of effect (after 1 or 6 mo).
Prescription Costs
Prescription costs of each NSAID and coxib prescription in
GPRD were estimated using the prescribed number of tables and
the 2006 cost data from the British National Formulary. The cost
data were converted from British pounds into US dollars using an
exchange of »1t oU S $2 (approximately the exchange rate at the
end of 2006). As prescription costs varied substantially and the use
of a single cost difference would be incorrect, the prescriptions of
conventional NSAIDs and coxibs were ranked by costs and the
incremental cost was based on the cost difference at each rank
between conventional NSAIDs and coxibs. In a sensitivity analysis,
the cost estimates from a recent UK assessment report were used
(US$5.60 per month for a conventional NSAID and US$41.28 for
a coxib) [31].
Simulation Model
Simulation methodology was used to estimate the incremental
cost of preventing one upper GI event during current exposure to
coxibs. The number of upper GI cases avoided by coxibs was
based on the RRR of the drug effect and the patient-specific
incidence of upper GI events as estimated in the Poisson
regression. The random variability was determined as follows.
The event probabilities were randomly selected from a normal
distribution on the basis of its mean and standard deviation. The
coxib RRR used in each simulation was randomly selected from a
normal distribution based on the RRR and 95% CI reported in
literature [58]. The simulation was repeated 250 times and
nonparametric bootstrapping techniques were then used to
estimate the 95% CIs (i.e., the 2.5% and 97.5% percentiles)
[59].
Results
Table 1 shows the rate of upper GI events in the large RCTs of
coxibs. Study patients were restricted to those who required long-
term NSAID exposure and the indication for treatment was mostly
OA or RA. Both the CLASS and VIGOR studies did not apply
‘‘intention to treat’’ statistical analyses, but restricted the analyses
to events that occurred during treatment or within 14 d of
discontinuation of treatment.
The GPRD study population included 971,426 patients
prescribed conventional NSAIDs and 148,592 prescribed coxibs.
A medical history of RA or OA was present in 23.0% of the
conventional NSAID users and 45.9% of the coxib users. They
were given a total of 8.5 million conventional NSAID prescriptions
and 0.9 million coxib prescriptions. The longitudinal prescription
histories indicated that a large proportion of patients used the
NSAIDs intermittently. Only about 34.5% of conventional
NSAID and 44.2% of coxib prescriptions were given to patients
with enough medication for longer term daily exposure (Table 2).
The RRs of upper GI events during current exposure (compared
to past exposure) were higher in those with continuous NSAID
exposure and lower with incidental exposure. As shown in Table 3,
the rate of upper GI events (as recorded by the GP) and of upper
GI hospitalizations during current exposure to conventional
NSAIDs decreased over calendar time by 5%–8% per year (p-
value for tests of linear trend ,0.0001 and 0.04, respectively). The
rate of upper GI hospitalizations during current exposure to
conventional NSAID users in GPRD was 12-fold lower than the
rate reported in the VIGOR RCT (3.8 and 45.0 per 1,000 person-
years, respectively).
The mean cost of a conventional NSAID prescription was
US$17.80 (range of US$4.56 at 5th percentile to US$47.36 at 95th
percentile). For coxibs, the mean cost was US$47.04 (range from
US$18.62 to US$83.96). The mean incremental cost of replacing a
conventional NSAID with a coxib was US$29.24. The mean cost
of preventing one clinical upper GI event by substituting the
conventional NSAID by a coxib was US$104k (95% CI US$74–
146k) using GPRD estimates for the risk of upper GI events
(Table 4). The cost effectiveness varied substantially by calendar
year and exposure characteristics (Figure 1). As shown in Table 4,
there was a large heterogeneity across the study population in the
costs of preventing one upper GI event. In patients with two or
more upper GI risk factors, 71.9% of the prescriptions had a cost
below US$100k per case avoided in long-term users while 36.6%
in intermittent users (with long gaps).
The cost-effectiveness estimates worsened with a delayed coxib
effect (Table 5). Conversely, the cost effectiveness of coxibs
improved substantially when using RCT data for the risk of upper
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(GPRD).
Study n Indication
Extent of NSAID
Exposure in
RCT Daily Dose Coxibs Rate of Upper GI Events
a
Conventional
NSAIDs Coxibs
Langman meta-analysis 1999 [44] 5,435 RA or OA Not reported 12.5–50 mg rofecoxib 26.0 13.3
VIGOR 2000 [45] 8,076 RA Daily for 11 mo 50 mg rofecoxib 45.0 21.0
CLASS 2000 [46] 8,059 RA or OA Daily for 6 mo 800 mg celecoxib 36.8 22.2
Goldstein meta-analysis 2000 [47] 9,144 RA or OA Not reported 50–800 mg celecoxib 16.8 2.0
ADVANTAGE 2003 [48] 5,557 OA Daily for 12 wk 25 mg rofecoxib 14.3 3.1
Watson meta-analysis 2004 [49] 17,072 RA or OA Not reported 12.5–50 mg rofecoxib 18.7 7.4
TARGET 2004 [50] 18,325 OA Daily for 1 y 400 mg lumiracoxib 9.1 3.2
SUCCESS 2006 [51] 13,274 OA Daily for 3 mo 200 or 400 mg celecoxib 21.1 10.0
MEDAL 2007 [52] 34,701 RA or OA Daily for 3 y 60 or 90 mg etoricoxib 9.7 6.7
Ramey meta-analysis [53] 5,441 RA, OA, or ankylosing
spondylitis
Not reported 60–120 mg etoricoxib 24.7 10.0
Actual clinical practice (GPRD) .1
million
Heterogeneous Variable Variable 6.0 (GP recorded) 5.9 (GP
recorded)
—— — — 3 . 8
(Hospitalization)
5.3.
(Hospitalization)
aNumber of cases per 1,000 person-years.
doi:10.1371/journal.pmed.1000194.t001
Table 2. Distribution of exposure characteristics of conventional NSAIDs and coxibs and RRs of upper GI events during current
exposure (compared to past exposure).
Exposure Characteristics
Percent
of Rx
Mean
Age
Women
(%)
GI Risk
Factors
(%)
OA or
RA (%)
Repeat
NSAID
Rx within
3m o
Crude RR of
GP Recorded
Upper GI
Events
(95% CI)
Crude RR of
Hospitaliza-
tion for Upper
GI Events
(95% CI)
Conventional NSAIDs
First-time 8.3% 57.8 52.9% 44.7% 9.5% 24.7% 1.9 (1.8–2.1) 1.6 (1.3–2.1)
Long gap 19.4% 60.9 57.6% 54.7% 24.6% 29.1% 1.5 (1.4–1.6) 1.2 (1.0–1.5)
Medication Very low 11.7% 64.3 59.6% 67.3% 39.1% 61.7% 1.9 (1.7–2.0) 1.9 (1.5–2.4)
Possession Low 9.7% 65.7 59.5% 72.1% 44.9% 78.8% 2.2 (2.0–2.4) 2.7 (2.1–3.4)
Ratio Moderate 8.8% 65.9 60.2% 72.4% 47.5% 85.7% 2.6 (2.4–2.8) 3.0 (2.3–3.9)
High Short-term use 7.7% 65.0 59.6% 68.6% 36.2% 71.7% 3.5 (3.2–3.7) 2.7 (2.0–3.6)
Medium-term 16.5% 67.2 61.2% 77.8% 51.0% 92.1% 3.5 (3.3–3.7) 3.2 (2.6–4.0)
Long-term 18.0% 68.5 63.1% 82.5% 54.9% 98.1% 4.0 (3.7–4.2) 4.8 (4.0–5.9)
Coxibs
First-time 2.7% 66.0 59.4% 69.7% 22.2% 39.7% 1.9 (1.3–2.7) 2.8 (1.8–4.5)
Long gap 10.1% 66.8 66.9% 73.5% 42.8% 44.4% 1.6 (1.3–1.9) 1.4 (1.0–2.0)
Medication Very low 8.5% 66.3 67.9% 73.4% 53.2% 65.4% 1.3 (1.0–1.7) 1.4 (0.9–2.1)
Possession Low 13.2% 67.3 67.0% 77.9% 57.7% 84.2% 1.6 (1.3–2.0) 1.2 (0.8–1.9)
Ratio Moderate 9.9% 67.3 68.2% 77.4% 58.0% 87.5% 1.7 (1.3–2.3) 1.0 (0.601.7)
High Short-term use 11.5% 68.7 67.7% 78.8% 47.2% 78.9% 2.4 (1.9–2.9) 2.4 (1.7–3.3)
Medium-term 19.2% 68.8 68.7% 81.6% 59.2% 92.6% 2.7 (2.2–3.2) 2.2 (1.7–3.0)
Long-term 25.0% 70.3 70.0% 86.0% 63.9% 97.3% 2.4 (2.0–2.9) 3.1 (2.4–4.0)
Each NSAID prescription wasclassifiedaccording to first-ever use, long gap (previous prescription at least 6 mo before), andshort gap (previous prescription within the last
6 mo). The medication possession ratio was estimated for the prescriptions issued after a short gap and divided into very low (,0.40), low (0.40–0.59), moderate (0.60–
0.79), and high (0.80+). Short-term use was defined #4 prescriptions in the 1 y before, medium-term 5–11, and long-term $11 prior NSAID prescriptions. Rx, prescription.
doi:10.1371/journal.pmed.1000194.t002
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and US$16k using the VIGOR RCT [45]).
Discussion
Health technology assessments frequently use data from
randomized trials for estimates of absolute risks of events and
patterns of drug use. Using coxibs as an example, we have shown
that cost-effectiveness analyses produced markedly different results
depending on the source of the data used in the modeling. The
cost effectiveness of coxibs was far worse when the analyses were
based on data from actual clinical practice rather than RCTs. The
use of data from actual clinical practice rather than RCTs would
have radically altered the conclusions of health technology
appraisals of coxibs.
There are several reasons for the substantive differences in
results using actual clinical practice or RCT data. The incidence of
upper GI events was lower among patients in GPRD compared to
those in RCTs. In GPRD, there was an almost 3-fold reduction
over calendar time in the incidence of upper GI events. This
Table 3. The incidence rate of upper GI events during current exposure to conventional NSAIDs or coxibs stratified by number of
risk factors and calendar time.
Risk Factor
Percent
of Rx GP Recorded Upper GI Events
Hospitalization for Upper
GI Events
a
No Cases Rate
b No Cases Rate
b
Conventional NSAIDs — — —— ——
Calendar year 1990–1993 17.5% 2,432 10.2 — —
1994–1997 23.4% 2,413 7.6 — —
1998–2001 31.8% 1,940 4.5 172 4.4
2002–2005 27.4% 1,414 3.7 664 3.7
Number of major upper GI risk factors 0 31.1% 1,334 2.5 93 1.1
1 31.1% 2,338 5.5 192 2.9
2+ 37.8% 4,742 10.5 571 7.7
Coxibs — —— — — —
Calendar year 2000–2001 13.2% 138 7.0 29 6.0
2002–2005 86.8% 600 5.7 249 5.3
Number of major upper GI risk factors 0 20.8% 64 2.1 15 1.2
1 29.3% 146 3.9 51 3.3
2+ 49.7% 537 9.1 214 8.6
aHospitalization data were derived from a subset of GPRD practices and covered the time period from 2001 to 2006.
bRate was the number of cases per 1,000 person-years.
Rx, prescription.
doi:10.1371/journal.pmed.1000194.t003
Table 4. The heterogeneity in the cost per case avoided with coxibs stratified by the number of major risk factors and exposure
characteristics (with the cost per case avoided estimated for each individual prescription).
Exposure Characteristics GP Recorded Upper GI Events
No Major Upper GI Risk Factor One Major Upper GI Risk Factor Two+ Major Upper GI Risk Factors
Percent
of Rx be-
low 100k
Percent
of Rx
100–200k
Percent
of Rx
200+k
Percent
of Rx be-
low 100k
Percent
of Rx
100–200k
Percent
of Rx
200+k
Percent
of Rx be-
low 100k
Percent
of Rx
100–200k
Percent
of Rx
200+k
First-time 11.1 22.0 66.8 31.0 28.1 40.9 51.7 26.0 22.3
Long gap 5.9 15.5 78.6 17.4 25.3 57.3 36.6 29.1 34.3
Medication Very low 5.7 18.3 76.0 16.0 25.2 58.8 31.0 26.4 42.6
Possession Low 8.9 25.0 66.1 23.7 31.3 45.0 44.0 30.6 25.4
Ratio Moderate 12.9 30.4 56.7 31.8 32.7 35.5 52.6 28.7 18.8
High Short-term use 16.8 34.5 48.7 33.0 36.6 30.4 56.9 29.5 13.6
Medium-term 23.1 35.0 41.9 43.1 33.9 23.0 64.9 24.7 10.4
Long-term 28.4 35.5 36.1 53.2 29.0 17.8 71.9 20.5 7.6
#Each NSAID prescription was classified according to first-ever use, long gap (previous prescription at least 6 mo before), and short gap (previous prescription within
the last 6 mo). The medication possession ratio was estimated for the prescriptions issued after a short gap and divided into very low (,0.40), low (0.40–0.59),
moderate (0.60–0.79), and high (0.80+). Short-term use was defined #4 prescriptions in the 1 y before, medium-term 5–11, and long-term $11 prior NSAID
prescriptions. Rx, prescription.
doi:10.1371/journal.pmed.1000194.t004
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rate of hospital admission for upper GI events [60]. Furthermore,
the cost-effectiveness analyses evaluated long-term daily use of
coxibs in patients with RA or OA, while most patients in actual
clinical practice did not have these conditions or used NSAIDs
intermittently or for short periods of time. A further difference in
the results of cost effectiveness may be related to the assumptions
for prescription costs. Single estimates for costs were used in
published cost-effectiveness models, while in daily practice there is
a substantive variability in prescription costs for NSAIDs. Lastly,
the published coxib cost-effectiveness studies described simple
scenarios of drug exposure and event probabilities assuming
Table 5. Sensitivity analyses of the population mean of the cost per case avoided with coxibs using different assumptions for
onset of coxib effect and event probabilities.
Model Assumptions
Mean Cost in US$ per
Case Avoided (95% CI)
Percent of Rx
below US$20k
Percent of Rx
below US$100k
Event probabilities based on rates observed in GPRD conventional NSAID users
Overall 104k (78–146k) 2.4 30.4
Onset of coxib upper GI effects: 1 month 212k (156–296k) 1.1 14.8
6m o .1 million 0 0
Coxib effect only in patients with long-term use with high medication
possession ratio (as studied in RCTs) and no effect in other patients
310k (222–430k) 1.1 10.7
Prescription costs based on UK assessment report [31] 144k (108–208k) 0.7 18.4
Event probabilities based on rates observed in GPRD coxib users 120k (56–208k) 2.6 31.3
Event probabilities based on rates observed in conventional NSAID users in RCTs
VIGOR RCT [45] 16k (12–20k) 77.9 99.0
CLASS RCT [46] 20k (16–26k) 57.7 98.8
Rofecoxib meta-analysis [44] 28k (22–38k) 16.5 98.0
Celecoxib meta-analysis [47] 42k (34–54k) 5.9 96.3
Etoricoxib meta-analysis [53] 28k (24–40k) 14.7 97.9
Rx, prescription.
doi:10.1371/journal.pmed.1000194.t005
Figure 1. The mean cost in US$ per case avoided with coxibs (and 95% CI) overall and stratified by the number of major risk
factors, calendar year, and exposure characteristics. Middle panel, GP recorded upper GI events; right panel, hospitalization for upper GI
events. The exposure characteristics of each NSAID prescription was classified according to first-ever use, long gap (previous prescription at least
6 mo before), and short gap (previous prescription within the last 6 mo). The medication possession ratio was estimated for the prescriptions issued
after a short gap and divided into very low (,0.40), low (0.40–0.59), moderate (0.60–0.79), and high (0.80+). Short-term use was defined as #4
prescriptions in the 1 y before, medium-term 5–11, and long-term $11 prior NSAID prescriptions. x-Axis, mean cost in US$ per case avoided; y-axis:
population subgroup.
doi:10.1371/journal.pmed.1000194.g001
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variability between patients in type of NSAID exposure, incidence
of upper GI events, and prescription costs. In this study, a large
proportion of the patients with a major upper GI risk factor,
recommended to be treated with coxibs in the UK [57], had a cost
per upper GI event avoided in excess of US$100k. The best
strategy for targeting coxibs cost-effectively to heterogeneous
populations has not yet been established. The use of coxibs has
now changed following the findings of cardiovascular harm [37].
This study did not address the appropriate prescribing of coxib on
the basis of our current understanding of these cardiovascular
risks.
RCTs provide the best evidence for establishing the efficacy
(relative effects) of a treatment and havehigh internal validity due
to randomization and blinding. But randomization and blinding
do not ensure that the absolute event probabilities and costs, as
observed in a RCT, will represent those in actual clinical practice
and that RCTs have external validity. The ‘‘real world’’ includes
an incredible diversity and complexity [61], while the ‘‘world of
RCTs’’ applies strict criteriaf o rp a t i e n ti n c l u s i o na n df o r
treatment exposure. RCTs often have an artificial design, with
more tests conducted and increased patient monitoring. Also,
patients may not comply with treatment instructions particularly
well in the ‘‘real’’ world, increasing costs and decreasing the
benefits. Thus, the absolute figures obtained from a RCT may
very well deviate fromand not representthe ‘‘real world.’’ On the
other hand, observational studies may provide reasonably good
estimates of absolute event probabilities and costs in patients in
actual clinical practice, but have major limitations in attributing
causality and estimating the relative effects of a drug treatment,
principally owing to confounding. Rather than considering
RCTs as the ideal evidence for all information, cost-effectiveness
studies could use could use meta-analyses of RCT data for the
drug effect estimates and observational data for the absolute
event probabilities and costs [62]. In addition to providing a
better context, this approach would also limit the possibility that
the best RCT data are selected for the cost-effectiveness analyses
[63]. An alternative and even better approach would be to use
large pragmatic RCTs for cost-effectiveness models. Pragmatic
RCTs are conducted with patients who represent the full
spectrum of the population to which the treatment might be
applied and with interventions that have real-life (rather than
ideal) compliance [64].
Cost-effectiveness analyses that are intended to guide medical
practice should consider the characteristics of all possible patient
subgroups that may be provided with the new technology. As an
example, the prevalence of risk factors, the incidence of upper
GI events, and the exposure characteristics of conventional
NSAID users in actual clinical practice could have been
described prior to assessing the cost effectiveness of coxibs.
Such an analysis wouldhave notedthe selective characteristics of
the patients enrolled in the large coxib RCTs and differences in
exposure characteristics. Few patients in GPRD used conven-
tional NSAIDs in the manner as tested in the coxib RCTs (i.e.,
long-term use with higher daily doses). Patients may not require
regular treatment, may not comply with dosage instructions, or
persist with treatment. A second consideration for cost-
effectiveness studies should be to evaluate the extent that RCT
evidence can be generalized and extrapolated to each of these
various patient subgroups that may be provided with the new
technology in actual clinical practice. As an example, it would
have been noted that most conventional NSAID users would not
have been eligible for inclusion into the large coxib RCTs and
that there is rather limited evidence for beneficial effects of
coxibs with short-term or intermittent use (as done by most
patients). While it may be impossible to conduct RCTs in
patients who use a treatment intermittently or who comply less
(because of the required sample size), the uncertainty in
generalizing RCT efficacy estimates to populations more diverse
in patient and treatment characteristics should be considered
explicitly [65]. None of the 33 published coxib cost-effectiveness
studies analysed the external validity of the assumptions used
[4–36]. They did not provide any guidance on the prescribing of
coxibs to the majority of patients using conventional NSAIDs in
actual clinical practice (e.g., those with short-term or intermit-
tent use). The field of health technology assessments should
move from evaluating cost efficacy in ideal (hypothetical)
populations with ideal interventions to cost effectiveness in real
populations with pragmatic interventions.
One of the key limitations of this study was that the classification
of upper GI events may have differed between RCTs and GPRD/
Hospital Episode Statistics. In most of the large RCTs, all
potential upper GI events were adjudicated in a standard manner.
In the CLASS celecoxib RCT, only one-third of the potential
cases were included in the analysis [46]. GPRD is based on
information diagnosed and collected in actual clinical practice.
This lack of case adjudication may have overestimated the rate of
upper GI events in GPRD. On the other hand, there may have
been under-diagnosis and/or under-recording in GPRD. Howev-
er, clinically significant events are generally well recorded in
GPRD, as documented by various validation studies [54].
Specifically, the validity of the diagnosis of upper GI bleeding in
the GPRD records was assessed in a sample of 96 people with a
diagnosis of upper GI bleeding recorded in their electronic
records. Hospital records were reviewed and the diagnosis
confirmed in 95 out of the sample of 96 patients [66].
In conclusion, the coxib cost-effectiveness studies lacked
external validity and more realistic estimates for event rates
and costs could have produced markedly different results,
sufficient to have led to different prescribing guidelines. External
validity should be an explicit requirement for cost-effectiveness
analyses.
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Background. Before a new treatment for a specific disease
becomes an established part of clinical practice, it goes
through a long process of development and clinical testing.
This process starts with extensive studies of the new
treatment in the laboratory and in animals and then moves
into clinical trials. The most important of these trials are
randomized controlled trials (RCTs), studies in which the
efficacy and safety of the new drug and an established drug
are compared by giving the two drugs to randomized
groups of patients with the disease. The final hurdle that a
drug or any other healthcare technology often has to jump
before being adopted for widespread clinical use is a health
technology assessment, which aims to provide policymakers,
clinicians, and patients with information about the balance
between the clinical and financial costs of the drug and its
benefits (its cost-effectiveness). In England and Wales, for
example, the National Institute for Health and Clinical
Excellence (NICE), which promotes clinical excellence and
the effective use of resources within the National Health
Service, routinely commissions such assessments.
Why Was This Study Done? Data on the risks of various
outcomes associated with a new treatment are needed for
cost-effectiveness analyses. These data are usually obtained
from RCTs, but although RCTs are the best way of
determining a drug’s potency in experienced hands under
ideal conditions (its efficacy), they may not be a good way to
determine a drug’s success in an average clinical setting (its
effectiveness). In this study, the researchers compare the
data from RCTs that have been used in several published
cost-effectiveness analyses of a class of drugs called selective
cyclooxygenase-2 inhibitors (‘‘coxibs’’) with observational
data from actual clinical practice. They then ask whether the
published cost-effectiveness studies, which generally used
RCT data, should have been used to inform coxib prescribing
policies. Coxibs are nonsteroidal anti-inflammatory drugs
(NSAIDs) that were developed in the 1990s to treat arthritis
and other chronic inflammatory conditions. Conventional
NSAIDs can cause gastric ulcers and bleeding from the gut
(upper gastrointestinal events) if taken for a long time. The
use of coxibs avoids this problem.
What Did the Researchers Do and Find? The researchers
extracted data on the real-life use of conventional NSAIDs
and coxibs and on the incidence of upper gastrointestinal
events from the UK General Practice Research Database
(GPRD) and from the national registry of hospitalizations.
Only a minority of the million patients who were prescribed
conventional NSAIDs (average cost per prescription
US$17.80) or coxibs (average cost per prescription
US$47.04) for a variety of inflammatory conditions took
them on a long-term daily basis, whereas in the RCTs of
coxibs, patients with a few carefully defined conditions took
NSAIDs daily for at least 6–9 months. The researchers then
developed a cost-effectiveness model to evaluate the costs
of the alternative strategies of prescribing a conventional
NSAID or a coxib. The mean additional cost of preventing
one gastrointestinal event recorded in the GPRD by using a
coxib instead of a NSAID, they report, was US$104,000; the
mean cost of preventing one hospitalization for such an
event was US$298,000. By contrast, the mean cost of
preventing one gastrointestinal event by using a coxib
instead of a NSAID calculated from data obtained in RCTs
was about US$20,000.
What Do These Findings Mean? These findings suggest
that the published cost-effectiveness analyses of coxibs
greatly underestimate the cost of preventing gastrointestinal
events by replacing prescriptions of conventional NSAIDs
with prescriptions of coxibs. That is, if data from actual
clinical practice had been used in cost-effectiveness analyses
rather than data from RCTs, the conclusions of the published
cost-effectiveness analyses of coxibs would have been
radically different and may have led to different prescribing
guidelines for this class of drug. More generally, these
findings provide a good illustration of how important it is to
ensure that cost-effectiveness analyses have ‘‘external’’
validity by using realistic estimates for event rates and
costs rather than relying on data from RCTs that do not
always reflect the real-world situation. The researchers
suggest, therefore, that health technology assessments
should move from evaluating cost-efficacy in ideal
populations with ideal interventions to evaluating cost-
effectiveness in real populations with real interventions.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000194.
N The UK National Institute for Health Research provides
information about health technology assessment
N The National Institute for Health and Clinical Excellence
Web site describes how this organization provides
guidance on promoting good health within the England
and Wales National Health Service
N Information on the UK General Practice Research Database
is available
N Wikipedia has pages on health technology assessment and
on selective cyclooxygenase-2 inhibitors (note that Wiki-
pedia is a free online encyclopedia that anyone can edit;
available in several languages)
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